CSL’s Flu Vaccine Aims For China Market
This article was originally published in PharmAsia News
CSL Biotherapies announced that following last September's FDA approval of its split virion flu vaccine, it has submitted an application to China's State FDA to bring the vaccine to China. To be sold under the brand Fluvax, it is likely to be introduced during the 2008-09 flu season. Experts point out that the local population still lack understanding of the importance of flu prevention, especially during an epidemic. However, with increasing awareness, the public demand for such vaccines is growing. The influx of international drug companies, which bring in the latest products and experience for preventing the disease, also helps to raise local awareness. (Click here for more - Chinese Language)
You may also be interested in...
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
For the first time, the US FDA granted an emergency use authorization to a device that allows for the home collection of saliva for COVID-19 diagnosis. See what Scott Rabuka, senior director of molecular products at DNA Genotek, which developed the test, said about it here.